Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.

Scope

Strategic Analysis of the Sales Outlook to 2012 for Big Pharma, Mid Pharma, Japan Pharma and Biotech Quantitative analysis of the revenue balance of launches and expiries for each peer set member to 2012 Assessment of current and forecast 2012 therapy area sales and molecule type focus for each peer set member

Highlights

Faced with failing growth, Big Pharma is expected to pursue strategic options including operational cost efficiencies, M&A with other Big Pharma companies, biotech, Mid Pharma CNS players and/or generics manufacturers and acquisitional moves outside of 'pharma space' to increase presence in medical devices, diagnostics and consumer healthcare.

Reasons to Purchase

Understand the strategic motives behind the recent wave of Big Pharma acquisitions of monoclonal antibody companies Identify the rare examples of promising high growth CNS products located in the Mid Pharma peer set Learn how biotech faces slowing growth momentum due to commercial pressures on therapeutic proteins.